Ultragenyx Pharmaceutical (RARE) Current Leases (2019 - 2025)

Ultragenyx Pharmaceutical (RARE) has 7 years of Current Leases data on file, last reported at $12.0 million in Q4 2025.

• Current Leases for Q4 2025 came in at $12.0 million, up 20.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $12.0 million (up 20.0% YoY), and the FY2025 annual result was $12.0 million, up 20.0% from the prior year.
• Current Leases slipped to $12.0 million in Q4 2025 per RARE's latest filing, from $12.1 million in the prior quarter.
• Over five years, Current Leases peaked at $12.8 million in Q1 2024 and troughed at $9.4 million in Q1 2021.
• A 5-year average of $11.3 million and a median of $11.5 million in 2022 frame the typical range for Current Leases.
• The sharpest annual moves came in 2021 and 2024: Current Leases jumped 37.42% in 2021, then declined 20.6% in 2024.
• A 5-year view of Current Leases shows it stood at $11.1 million in 2021, then climbed by 6.44% to $11.8 million in 2022, then grew by 6.93% to $12.6 million in 2023, then decreased by 20.6% to $10.0 million in 2024, then increased by 20.0% to $12.0 million in 2025.
• Business Quant data shows RARE's Current Leases at $12.0 million in Q4 2025, $12.1 million in Q3 2025, and $11.8 million in Q2 2025.